Most breast cancer genomes have a complex mutation landscape. Somatic alterations have been found mainly in breast cancer patients of European ancestry; In the current study, full exome sequencing (WES) was conducted from tumors extracted from and matched to adjacent normal tissue samples from 11 early onset breast cancer patients included in the Shanghai breast cancer study. We found 159 somatic missense and 10 ridiculous mutations distributed in 167 genes. The most frequent 50 somatic mutations identified by Wes were selected for verification using the sequinoma array system in 11 breast cancer patients, and an additional 433 tumors and 921 normal tissue/blood samples were taken from the Shanghai Breast Cancer Study. Of these 50 mutations.
(Get 15% Discount on Buying this Report)
Market Segments
Company profiles
- Illumina
- Thermo Fisher
- Roche
- Angilent
- Eurofins
- Sengenics
- Ambry
- Macrogen
- BGI
- Novo Gene
By Product Type
- Agilent HaloPlex
- Agilent SureSelect
- Agilent SureSelect QXT
- Illumina TruSeq Exome
- Roche Nimblegen SeqCap
- MYcroarray MYbaits
By Application
- Correlation Research of Normal Human
- Mendelian Disease and Rare Syndrome Gene Discovery
- The Research of Complex Diseases
- Mouse Exome Sequencing
A full report is available at: https://orionmarketreports.com/whole-exome-sequancing/83587/
Scope of the Report
The research study analyzes the global Intravenous Equipment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions , considering multiple aspects some of which are listed below as:
Recent Developments
o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment
Geographic Coverage
o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume
